Genotype-Identical Siblings with Cartilage-Hair Hypoplasia Show Divergent Growth Hormone Responses

Cartilage-hair hypoplasia causes severe short stature and divergent responses to recombinant human growth hormone treatment in two siblings with identical RMRP gene variants, Cureus reported.

The condition, an autosomal recessive skeletal dysplasia, stems from biallelic variants in the non-coding RMRP gene. Affected children present with disproportionate short stature, sparse fine hair, and variable immunological and gastrointestinal involvement.

Medical literature offers limited evidence on treating this specific skeletal dysplasia with recombinant human growth hormone. Endocrine specialists frequently face questions regarding whether growth hormone can improve height in these patients.

The boy showed a clear increase in growth velocity and height standard deviation score during treatment. The girl experienced only a minimal and transient response to the exact same pharmacological intervention.

In Plain English: The Clinical Takeaway

  • Mechanism of action: Recombinant human growth hormone stimulates somatic growth and cellular replication by binding to specific membrane receptors, though its efficacy in skeletal dysplasias remains highly variable.
  • Subnormal stimulation tests: Both pediatric patients showed inadequate hormonal output during standard pharmacological testing, prompting the initial off-label endocrine therapy.
  • Metabolic monitoring: Long-term clinical surveillance must track insulin resistance and T-cell lymphopenia, as both siblings developed obesity-related metabolic changes regardless of their linear growth outcomes.

Genetics and clinical evaluation

Sequencing at the Manchester Centre for Genomic Medicine found the same compound heterozygous variants in both children. Testing confirmed carrier status in the non-consanguineous parents, placing the variants in trans.

Patient 1 was born at 39 weeks after maternal pre-eclampsia with a birth weight of 3060 grams. He exhibited short limbs on prenatal scans and was referred at 10 months for severe short stature.

Patient 2 presented with similar skeletal features and was evaluated alongside her brother. Both siblings were prepubertal when recombinant human growth hormone therapy was initiated and subsequently discontinued.

Clinical Feature Patient 1 (Male) Patient 2 (Female)
Molecular Diagnosis Compound heterozygous RMRP variants Compound heterozygous RMRP variants
Growth Hormone Response Clear increase in height SDS Minimal and transient response
Immunological Phenotype Mild T-cell lymphopenia Clinically more severe T-cell lymphopenia
Metabolic Complications Insulin resistance / HOMA-IR elevation Insulin resistance / HOMA-IR elevation

Metabolic and immunological surveillance

Both siblings later developed obesity-related metabolic changes, including insulin resistance estimated by homeostasis model assessment. T-cell lymphopenia was present in both children but proved clinically more severe in the girl.

General safety concerns for recombinant human growth hormone include slipped capital femoral epiphysis, progression of scoliosis, intracranial hypertension, and impaired glucose tolerance. These risks carry added weight in children whose skeletons are inherently dysplastic.

The underlying predisposition to malignancy and cellular immunodeficiency introduces theoretical concerns that demand rigorous longitudinal tracking. Regular immunological and endocrine evaluations remain essential for all pediatric patients carrying confirmed RMRP variants.

Contraindications & When to Consult a Doctor

Recombinant human growth hormone therapy is contraindicated in patients with active malignancy, closed epiphyses, or known hypersensitivity to somatropin. Clinicians must exercise extreme caution in skeletal dysplasias due to risks of exacerbating spinal deformities, intracranial pressure, or impaired glucose metabolism.

The Manchester Centre for Genomic Medicine collaborates with the University of Manchester to deliver the MSc in Genomic Medicine, training clinicians to apply genomic technologies and bioinformatics to patient care. The programme draws on the centre’s expertise in clinical variant interpretation and disease modelling, with optional course units covering inherited diseases and genomics in infectious diseases.

Parents should consult a pediatric endocrinologist immediately if a child with cartilage-hair hypoplasia exhibits severe headaches, visual disturbances, limping, joint pain, or rapid, unexplained weight gain during endocrine treatments.

References

Photo of author

Health Desk

Health Desk at Archyde.

Rosalía Wins Four Awards at LOS40 Music Awards 2026 in Barcelona

U.S. Army Seeks Stinger Replacement Under $200,000